Recombinant Human CT47A1 Protein，His

CT47A1, a member of the CT (cancer/testis) antigen family, has garnered attention in cancer immunotherapy research due to its restricted expression pattern. Primarily expressed in testicular germ cells and various cancerous tissues, CT47A1 is not present in normal somatic tissues, making it an ideal candidate for targeted therapeutic strategies. The investigation of CT47A1 is rooted in its potential role as a biomarker for cancer diagnosis and prognosis, particularly in malignancies such as melanoma, lung cancer, and breast cancer. Its unique expression profile suggests that it could serve as a target for cancer vaccines and adoptive T-cell therapies, highlighting its relevance in the development of personalized immunotherapeutic approaches. Furthermore, understanding the molecular mechanisms regulating CT47A1 expression may provide insights into tumorigenesis and immune evasion strategies utilized by cancer cells. Recent studies have focused on characterizing the immunogenicity of CT47A1, aiming to develop novel vaccines that induce robust immune responses against tumors expressing this antigen. Overall, research on CT47A1 not only contributes to the broader understanding of cancer biology but also holds promise for advancing treatment options through immunotherapy.